PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20567598-3 2010 Here, we report the identification of the 5-lipoxygenase inhibitors, NDGA, AA861, and MK886, as potent blockers of the TRPM7 channel. MK-886 86-91 arachidonate 5-lipoxygenase Homo sapiens 42-56 24168271-8 2013 Production of leukotriene B4 was associated with an increase in 5-lipoxygenase expression in human neutrophils; addition of MK886 (a 5-lipoxygenase activating protein inhibitor) attenuated further increase in leukotriene B4 production. MK-886 124-129 arachidonate 5-lipoxygenase Homo sapiens 133-147 23762565-2 2013 Cells were treated with olanzapine and a 5-lipoxygenase (5-LOX) activating protein (FLAP) inhibitor MK-886. MK-886 100-106 arachidonate 5-lipoxygenase Homo sapiens 41-55 23762565-2 2013 Cells were treated with olanzapine and a 5-lipoxygenase (5-LOX) activating protein (FLAP) inhibitor MK-886. MK-886 100-106 arachidonate 5-lipoxygenase Homo sapiens 57-62 21993002-4 2011 The present study provides evidence that combined use of celecoxib and 5-LOX inhibitor MK886 markedly suppresses pancreatic tumor cell growth in vitro. MK-886 87-92 arachidonate 5-lipoxygenase Homo sapiens 71-76 21993002-6 2011 We found that MK886 reversed celecoxib-induced increases in 5-LOX gene expression and Erk1/2 activation in pancreatic tumor cells. MK-886 14-19 arachidonate 5-lipoxygenase Homo sapiens 60-65 20061081-7 2010 MK886 (5-LOX activating protein inhibitor) mediated the induction of apoptosis by elevation of caspase-3 and Bax/Bcl2 ratio. MK-886 0-5 arachidonate 5-lipoxygenase Homo sapiens 7-12 22293202-3 2012 We found that the treatment of MK886 (an inhibitor of 5-LOX) or knockdown of 5-LOX was able to downregulate the expression of NF-kappaB p65 at the mRNA level and decreased the phosphorylation level of inhibitor kappaBalpha (IkappaBalpha) in the cytoplasm of hepatoma HepG2 or H7402 cells, which resulted in the decrease of the level of nuclear NF-kappaB p65. MK-886 31-36 arachidonate 5-lipoxygenase Homo sapiens 54-59 22068350-6 2012 Similar reduction was achieved by MK-886, an inhibitor of 5-LOX activating protein but the above differences were not statistically significant. MK-886 34-40 arachidonate 5-lipoxygenase Homo sapiens 60-63 21643005-10 2011 Moreover, treatment of LM-MCF-7 cells with the specific 5-LOX inhibitor MK-886 (20-40 mumol/L) or 5-LOX siRNA (50-100 nmol/L) decreased the promoter activity of FASN. MK-886 72-78 arachidonate 5-lipoxygenase Homo sapiens 56-61 19239910-0 2009 MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation. MK-886 0-6 arachidonate 5-lipoxygenase Homo sapiens 28-42 20126469-7 2010 Moreover, we found that 5-lipoxygenase (5-LOX) was responsible for the up-regulation of FAS by using MK886 (an inhibitor of 5-LOX) and 5-LOX small interfering RNA. MK-886 101-106 arachidonate 5-lipoxygenase Homo sapiens 24-38 20126469-7 2010 Moreover, we found that 5-lipoxygenase (5-LOX) was responsible for the up-regulation of FAS by using MK886 (an inhibitor of 5-LOX) and 5-LOX small interfering RNA. MK-886 101-106 arachidonate 5-lipoxygenase Homo sapiens 40-45 20364155-6 2010 And the effect of MK886, a specific inhibitor of 5-lipoxygenase (5-LOX), on OPN promoter activity and mRNA expression in HepG2-X Delta 127 and H7402-X Delta 127 cells were examined using luciferase reporter gene assays and RT-PCR, respectively. MK-886 18-23 arachidonate 5-lipoxygenase Homo sapiens 65-70 19239910-1 2009 MK-886, an inhibitor of the 5-lipoxygenase-activating protein (FLAP), potently suppresses leukotriene biosynthesis in intact cells and is frequently used to define a role of the 5-lipoxygenase (EC 1.13.11.34) pathway in cellular or animal models of inflammation, allergy, cancer, and cardiovascular disease. MK-886 0-6 arachidonate 5-lipoxygenase Homo sapiens 28-42 19239910-1 2009 MK-886, an inhibitor of the 5-lipoxygenase-activating protein (FLAP), potently suppresses leukotriene biosynthesis in intact cells and is frequently used to define a role of the 5-lipoxygenase (EC 1.13.11.34) pathway in cellular or animal models of inflammation, allergy, cancer, and cardiovascular disease. MK-886 0-6 arachidonate 5-lipoxygenase Homo sapiens 178-192 16545574-0 2006 Pre-treatment of HT-29 cells with 5-LOX inhibitor (MK-886) induces changes in cell cycle and increases apoptosis after photodynamic therapy with hypericin. MK-886 51-57 arachidonate 5-lipoxygenase Homo sapiens 34-39 18771933-1 2008 In our previous study we have proved that colon cancer cells HT-29 pre-treated with specific 5-lipoxygenase inhibitor MK-886 became more susceptible to photodynamic therapy (PDT) with hypericin and we also found that this mutual combination induced cell cycle arrest and stimulated onset of apoptosis (Kleban et al., 2007. MK-886 118-124 arachidonate 5-lipoxygenase Homo sapiens 93-107 17319946-7 2007 Nordihydroguaiaretic acid (NDGA), a non-selective lipoxygenase inhibitor, and MK886, a specific inhibitor of 5-lipoxygenase, induced MMP-3 expression synergistically with IL-1. MK-886 78-83 arachidonate 5-lipoxygenase Homo sapiens 109-123 17121918-0 2006 Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. MK-886 32-37 arachidonate 5-lipoxygenase Homo sapiens 14-28 16547963-9 2006 In conclusion, intrapulmonary application of the 5-lipoxygenase inhibitor MK886 with surfactant as a carrier improves lung function by decreasing EVLW as the main response to LTB(4) reduction. MK-886 74-79 arachidonate 5-lipoxygenase Homo sapiens 49-63 12660222-3 2003 5-LOX inhibitors, 5,8,11,14-eicosatetraynoic acid and caffeic acid, completely prevented apoptosis, whereas the phospholipase A(2) inhibitor methyl-arachidonoyl fluorophosphonate and the 5-LOX activating protein inhibitor MK886 reduced it to 65-70%. MK-886 222-227 arachidonate 5-lipoxygenase Homo sapiens 0-5 15899809-2 2005 We have previously reported that exposure to the 5-lipoxygenase activating protein-directed inhibitor MK886 but not the cyclooxygenase inhibitor, indomethacin, reduced growth, increased apoptosis, and up-regulated PPARalpha and gamma expression in breast cancer cell lines. MK-886 102-107 arachidonate 5-lipoxygenase Homo sapiens 49-63 15454480-5 2005 At a concentration of 100 nM, the drugs BWA4C (a specific 5-lipoxygenase inhibitor) and MK-886 (a specific 5-lipoxygenase activating protein inhibitor) markedly inhibited CD40-induced DNA synthesis (45% and 38%, respectively) and CD40-induced expression of CD23, CD54, and CD150. MK-886 88-94 arachidonate 5-lipoxygenase Homo sapiens 107-121 15630695-5 2005 The ability of iPLA2 inhibitors to increase GluR1 phosphorylation was mimicked by the 5-lipoxygenase (5-LO) inhibitor MK-886, but not by blockers of 12-lipoxygenase (12-LO) or cyclooxygenase. MK-886 118-124 arachidonate 5-lipoxygenase Homo sapiens 86-100 15517864-1 2004 BACKGROUND: MK 886, a 5-lipoxygenase inhibitor, induces a type 1 "apoptotic" form of programmed cell death in Bcl-2-positive U937 monoblastoid cells. MK-886 12-18 arachidonate 5-lipoxygenase Homo sapiens 22-36 15132836-5 2004 RESULTS: 5-Lipoxygenase inhibitors nordihydroguaiaretic acid, AA861 and MK886, could suppress the expression of ICAM-1 protein as well as of its mRNA in a375 cells and reduce the adhesion of a375 to EC304. MK-886 72-77 arachidonate 5-lipoxygenase Homo sapiens 9-23 16551867-1 2006 The small molecular inhibitor MK886 is known to block 5-lipoxygenase-activating protein ALOX5AP and shows antitumor activity in multiple human cell lines. MK-886 30-35 arachidonate 5-lipoxygenase Homo sapiens 54-68 14656710-17 2004 MK886, a selective 5-lipoxygenase inhibitor, inhibited OxAA stimulation of LTB(4) and IL-8 also in a dose-response manner. MK-886 0-5 arachidonate 5-lipoxygenase Homo sapiens 19-33 12394960-11 2002 The employment of a platelet-activating factor receptor antagonist (WEB 2086) blocked leukotriene synthesis, and both WEB 2086 and a 5-lipoxygenase inhibitor (MK-886) suppressed the respiratory burst linked with this second priming pathway. MK-886 159-165 arachidonate 5-lipoxygenase Homo sapiens 133-147 11311496-1 2001 The 5-lipoxygenase inhibitors SC41661A and MK886 with different mechanisms of action and the free radical spin trap, NTBN inhibit proliferation of the human bronchiolar lung cancer cell line NCI H-358 (5807 CRL). MK-886 43-48 arachidonate 5-lipoxygenase Homo sapiens 4-18 12033433-6 2002 Although the 5-LOX activating protein inhibitor MK886 killed these cells, another 5-LOX inhibitor AA861 hardly showed any effect. MK-886 48-53 arachidonate 5-lipoxygenase Homo sapiens 13-18 12054916-0 2002 Increased cytosol Ca(2+) and type 1 programmed cell death in Bcl-2-positive U937 but not in Bcl-2-negative PC-3 and Panc-1 cells induced by the 5-lipoxygenase inhibitor MK 886. MK-886 169-175 arachidonate 5-lipoxygenase Homo sapiens 144-158 12054916-1 2002 MK 886, an arachidonic acid-related analog which inhibits the enzyme, 5-lipoxygenase by an indirect mechanism involving the 5-lipoxygenase activating protein, rapidly increased U937 cytosol Ca(2+), much of which localized around the cell nuclei. MK-886 0-6 arachidonate 5-lipoxygenase Homo sapiens 70-84 12054916-1 2002 MK 886, an arachidonic acid-related analog which inhibits the enzyme, 5-lipoxygenase by an indirect mechanism involving the 5-lipoxygenase activating protein, rapidly increased U937 cytosol Ca(2+), much of which localized around the cell nuclei. MK-886 0-6 arachidonate 5-lipoxygenase Homo sapiens 124-138 9789062-6 1998 Inhibition of 5-lipoxygenase by MK886 completely blocks 5-HETE production and induces massive apoptosis in both hormone-responsive (LNCaP) and -nonresponsive (PC3) human prostate cancer cells. MK-886 32-37 arachidonate 5-lipoxygenase Homo sapiens 14-28 11333152-6 2001 In summary, the results indicate that during the application of MK-886 as a 5;-lipoxygenase inhibitor in neutrophils, the impact of the compound on the functional activity of the cells should be taken into consideration. MK-886 64-70 arachidonate 5-lipoxygenase Homo sapiens 76-91 10953307-0 2000 A genomic response of H-358 bronchiolar carcinoma cells to MK 886, an inhibitor of 5-lipoxygenase, assessed with a cDNA array. MK-886 59-65 arachidonate 5-lipoxygenase Homo sapiens 83-97 10600493-4 1999 Consistently, incubation of CHP100 cells with inhibitors of 5-lipoxygenase (5,8,11,14-eicosatetraynoic acid and MK886) reduced light emission and PCD, whereas inhibition of catalase by 3-amino-1, 2,4-triazole enhanced both processes. MK-886 112-117 arachidonate 5-lipoxygenase Homo sapiens 60-74 9845549-9 1998 Treatment of neutrophils with an inhibitor of 5-lipoxygenase-activating protein (MK886) and thus synthesis of leukotrienes (LTs) or with an antagonist of the LTB4 receptor (LY223982) blocked the release of elastase. MK-886 81-86 arachidonate 5-lipoxygenase Homo sapiens 46-60 9792133-8 1998 MK886, a 5-lipoxygenase-inhibitor with a different mechanism of action, induced nonnecrotic changes largely confined to the cytoplasm, most consistent with type 2 "autophagic" programmed cell death. MK-886 0-5 arachidonate 5-lipoxygenase Homo sapiens 9-23 10913156-8 2000 Moreover, 5-lipoxygenase inhibitors 5,8,11,14-eicosatetraynoic acid and MK886, cyclooxygenase inhibitor indomethacin, caspase-3 and caspase-9 inhibitors Z-DEVD-FMK and Z-LEHD-FMK, but not nitric oxide synthase inhibitor Nomega-nitro-l-arginine methyl ester, significantly reduced the cell death-inducing effect of AEA. MK-886 72-77 arachidonate 5-lipoxygenase Homo sapiens 10-24 10493497-8 1999 The cyclooxygenase inhibitor aspirin and the 5-lipoxygenase inhibitor MK-886 both partially inhibited DNA synthesis in response to NNK. MK-886 70-76 arachidonate 5-lipoxygenase Homo sapiens 45-59 10628326-0 1999 Altered oncogene, tumor suppressor and cell-cycle gene expression in PANC-1 cells cultured with the pleiotrophic 5-lipoxygenase inhibitor, MK886, assessed with a gene chip. MK-886 139-144 arachidonate 5-lipoxygenase Homo sapiens 113-127 9742967-4 1998 In addition, 5-lipoxygenase was activated by tamoxifen and the specific enzyme inhibitor, MK886, protected K562 cells against the drug. MK-886 90-95 arachidonate 5-lipoxygenase Homo sapiens 13-27 1748650-3 1991 In addition, we have shown inhibition of A23187- and fMLP-induced 5-lipoxygenase translocation by an indole and a quinoline leukotriene synthesis inhibitor, MK-886 and L-674,573, respectively. MK-886 157-163 arachidonate 5-lipoxygenase Homo sapiens 66-80 9639560-4 1998 Consistent with this observation, selective inhibitors of prostaglandin H synthase (i.e. indomethacin) and 5-lipoxygenase (i.e. MK886 and caffeic acid) protected CHP100 cells against gp120-induced necrosis. MK-886 128-133 arachidonate 5-lipoxygenase Homo sapiens 107-121 9550202-9 1998 5-lipoxygenase inhibitor MK-886 (100 nM) lifts the inhibitory effect of arachidonate. MK-886 25-31 arachidonate 5-lipoxygenase Homo sapiens 0-14 9103531-4 1997 The data show that the dual inhibition of 5-lipoxygenase and HLE is unique to boswellic acids: other pentacyclic triterpenes with HLE inhibitory activities (e.g., ursolic acid and amyrin) do not inhibit 5-lipoxygenase, and leukotriene biosynthesis inhibitors from different chemical classes (e.g., NDGA, MK-886 and ZM-230,487) do not impair HLE activity. MK-886 304-310 arachidonate 5-lipoxygenase Homo sapiens 42-56 8551795-7 1995 Characteristic ultrastructural changes of apoptosis were seen at 120 h. MK886, an inhibitor of 5-lipoxygenase with a mechanism of action distinct from oxidation/reduction reagents, at 20-40 microM also inhibited CML and U937 cell proliferation and induced apoptosis, as shown by DNA laddering and ultrastructure. MK-886 72-77 arachidonate 5-lipoxygenase Homo sapiens 95-109 7669639-1 1995 MK-886, a leukotriene biosynthesis inhibitor, which prevents the translocation and activation of 5-lipoxygenase, has been proposed as an effective drug for the treatment of inflammatory disorders, including psoriasis. MK-886 0-6 arachidonate 5-lipoxygenase Homo sapiens 97-111 7840141-3 1995 In contrast, Thap had very little effect on the activation of PLA2 when 5-lipoxygenase (5-LO) was blocked by BW755C or MK-886, whereas A-23187 caused a substantial activation. MK-886 119-125 arachidonate 5-lipoxygenase Homo sapiens 72-86 8058773-2 1994 Treatment with either Zileuton (a specific reversible competitive inhibitor of 5-lipoxygenase) or MK886 (a specific irreversible inhibitor of the 5-lipoxygenase activator protein) prevented stimulated neutrophil adherence and chemotaxis (but not superoxide anion production) in vitro. MK-886 98-103 arachidonate 5-lipoxygenase Homo sapiens 146-160 1314503-4 1992 In contrast, LTB4 release correlated with the translocation of 5-lipoxygenase from the cytosol to the membrane fraction of the cells following A23187 stimulation and was inhibited by MK-886. MK-886 183-189 arachidonate 5-lipoxygenase Homo sapiens 63-77 9696418-3 1998 It was clearly demonstrated that two structurally different inhibitors of 5-lipoxygenase metabolism, i.e., 3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-di methyl propanoic acid (MK-886) and esculetin, significantly potentiated the HL-60 cell differentiation induced by retinoic acid or DMSO. MK-886 107-195 arachidonate 5-lipoxygenase Homo sapiens 74-88 9696418-3 1998 It was clearly demonstrated that two structurally different inhibitors of 5-lipoxygenase metabolism, i.e., 3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-di methyl propanoic acid (MK-886) and esculetin, significantly potentiated the HL-60 cell differentiation induced by retinoic acid or DMSO. MK-886 197-203 arachidonate 5-lipoxygenase Homo sapiens 74-88 9615721-1 1998 The 5-lipoxygenase inhibitors ETYA, SC41661A and MK886 reduced the proliferation and viability of Panc-1 human pancreatic cancer cells. MK-886 49-54 arachidonate 5-lipoxygenase Homo sapiens 4-18 9615721-11 1998 When gamma linolenic acid was combined with MK886, the more effective of the two 5-lipoxygenase inhibitors, a synergistic reduction in Panc-1 cell number and viability occurred. MK-886 44-49 arachidonate 5-lipoxygenase Homo sapiens 81-95 9585079-1 1998 MK-886, a specific inhibitor of 5-lipoxygenase inhibited DNA replication in leukemic HL-60 cells in a dose-dependent manner. MK-886 0-6 arachidonate 5-lipoxygenase Homo sapiens 32-46 9435558-5 1997 However, significant inhibition was noted after treatment with either MK-886 (5-lipoxygenase inhibitor) or a nitric oxide (NO) donor (diethylenetriamine/NO). MK-886 70-76 arachidonate 5-lipoxygenase Homo sapiens 78-92 9261338-1 1997 It was clearly demonstrated that two structurally different inhibitors of 5-lipoxygenase (5-LPO) metabolism (leukotriene synthesis), i.e. MK-886 and esculetin, when combined with transforming growth factor-beta 1 (TGF-beta 1), significantly enhanced the differentiation but did not change proliferation (i.e. cell number and cell cycle parameters) of human leukemia HL-60 cells in vitro. MK-886 138-144 arachidonate 5-lipoxygenase Homo sapiens 74-88 9044439-1 1997 Micromolar MK886, a selective inhibitor of 5-lipoxygenase at nanomolar concentration, induces physiologic cell death in U937 and chronic myelogenous leukemia blast cells. MK-886 11-16 arachidonate 5-lipoxygenase Homo sapiens 43-57 8917356-0 1996 An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells. MK-886 40-45 arachidonate 5-lipoxygenase Homo sapiens 24-38 8917356-1 1996 MK886 (Merck Frosst) is a selective in vivo inhibitor of 5-lipoxygenase, active at nanomolar concentrations. MK-886 0-5 arachidonate 5-lipoxygenase Homo sapiens 57-71 8917356-8 1996 Since MK886 inhibits the association of arachidonic acid with the 5-lipoxygenase activating protein, altered arachidonic acid metabolism may have contributed to these results. MK-886 6-11 arachidonate 5-lipoxygenase Homo sapiens 66-80 7484419-12 1995 MK-886, which inhibits the translocation of 5-lipoxygenase (5-LO) from the cytosol and its binding to the membranal 5-LO activating enzyme, suppressed dose-dependently follicular rupture from the treated ovary. MK-886 0-6 arachidonate 5-lipoxygenase Homo sapiens 44-58 1429555-4 1992 Accumulation of active membrane-associated 5-lipoxygenase was inhibited and reversed by the 5-lipoxygenase translocation inhibitor MK-886. MK-886 131-137 arachidonate 5-lipoxygenase Homo sapiens 43-57 1429555-4 1992 Accumulation of active membrane-associated 5-lipoxygenase was inhibited and reversed by the 5-lipoxygenase translocation inhibitor MK-886. MK-886 131-137 arachidonate 5-lipoxygenase Homo sapiens 92-106 1429555-7 1992 The ability to metabolize hydroxy fatty acids was dependent upon 5-lipoxygenase-activating protein association, but was lost if 5-lipoxygenase was eluted from the membrane by MK-886. MK-886 175-181 arachidonate 5-lipoxygenase Homo sapiens 128-142 1857337-1 1991 An indole class of leukotriene synthesis inhibitors, exemplified by MK-886, which does not directly inhibit 5-lipoxygenase, has been shown to bind to an 18-kDa leukocyte membrane protein and to inhibit 5-lipoxygenase membrane translocation. MK-886 68-74 arachidonate 5-lipoxygenase Homo sapiens 202-216 1793062-6 1991 The mechanism of action of MK-886 has been found to be the inhibition of activation of the 5-lipoxygenase enzyme. MK-886 27-33 arachidonate 5-lipoxygenase Homo sapiens 91-105 1900463-6 1991 These data also indicate that MK-886, a novel inhibitor of 5-lipoxygenase product formation, is a potentially useful leukotriene inhibitor which does not affect monokine production. MK-886 30-36 arachidonate 5-lipoxygenase Homo sapiens 59-73 1846160-9 1991 LTB4 release in response to all stimuli tested was inhibited by MK-886, a drug that binds to 5-lipoxygenase-activating protein. MK-886 64-70 arachidonate 5-lipoxygenase Homo sapiens 93-107 2164857-2 1990 We have investigated the inhibitory activity of compound MK-886 (formerly L-663,536), an indole derivative, on 5-lipoxygenase product synthesis in various human phagocytes stimulated with either the ionophore A23187, in the presence and absence of exogenous arachidonic acid, or platelet-activating factor (PAF). MK-886 57-63 arachidonate 5-lipoxygenase Homo sapiens 111-125 2164857-8 1990 MK-886 inhibited 5-lipoxygenase product synthesis in A23187-stimulated blood eosinophils and monocytes, and in neutrophils primed with granulocyte-macrophage colony-stimulating factor and stimulated with PAF with IC50 values of 1-13 nM. MK-886 0-6 arachidonate 5-lipoxygenase Homo sapiens 17-31 30819230-10 2019 Similar to that of TRPM7 silencing, treatment with MK886, a potent 5-lipoxygenase inhibitor to reduce TRPM7 expression, and/or BAPTA-AM, an intracellular calcium chelator, significantly mitigated the Epidermal growth factor (EGF) or Insulin-like growth factors (IGF)-stimulated migration, invasion, and the EMT in ovarian cancer cells by decreasing the levels of intracellular calcium [Ca2+]i. MK-886 51-56 arachidonate 5-lipoxygenase Homo sapiens 67-81 2104841-0 1990 MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. MK-886 0-5 arachidonate 5-lipoxygenase Homo sapiens 112-126 2104841-3 1990 3-[1-(p-Chlorobenzyl)-5-(isopropyl)-3-tert-butylthioindol-2-yl]-2, 2- dimethylpropanoic acid (MK886) is a potent and specific inhibitor of leukotriene biosynthesis in vivo and in intact cells, but has no direct effect on 5-lipoxygenase activity in cell-free systems. MK-886 94-99 arachidonate 5-lipoxygenase Homo sapiens 221-235 2104841-4 1990 In this report, we show that MK886 can both prevent and reverse the membrane translocation of 5-lipoxygenase, in conjunction with the inhibition of leukotriene synthesis. MK-886 29-34 arachidonate 5-lipoxygenase Homo sapiens 94-108 2104841-7 1990 Attempts to demonstrate the effects of MK886 on the association of 5-lipoxygenase with membrane in cell-free preparations failed due to a nonspecific Ca2+-dependent sedimentation of the enzyme. MK-886 39-44 arachidonate 5-lipoxygenase Homo sapiens 67-81 2104841-8 1990 The mechanism of action of MK-886 is therefore to block translocation, prevent subsequent activation of 5-lipoxygenase, and hence block cellular leukotriene biosynthesis. MK-886 27-33 arachidonate 5-lipoxygenase Homo sapiens 104-118